Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon
cancel membership anytime before next billing cycle to avoid charges Full refund for visit if PlushCare cannot treat you, connectivity issues hinder consultation, your doctor is over 10 minutes late, or state licensing prevents the visit (medication and lab costs excluded) No refunds once a clinical assessment or medical advice is provided, even without a prescription Trust and Transparency PlushCare is up-front about visit pricing, and insured patients often pay standard copays
Bloating from semaglutide is typically most pronounced during the initial weeks of treatment and dose escalation periods
This hormone helps control appetite, so users will typically eat less
Bettadapura S et al
Discuss any changes to diet or exercise with your healthcare provider